Skip NavigationSkip to Content
Rare Tumors Initiative Symposium
Strategies to develop therapies for rare tumors: Small numbers, but big opportunities

June 17, 2015
Top Right Header
Spacer image Spacer
Spacer Strategies to develop therapies for rare tumors: Small numbers, but big opportunities

Rare Tumors Initiative Symposium

June 17, 2015
Natcher Conference Center, Balcony A
National Institutes of Health
45 Center Dr., Bethesda, MD

This meeting is sponsored by ORDR, NCATS and by CCR, NCI.

As a better understanding of cancer mechanisms is developing, more therapies are becoming available to evaluate in clinical trials. Rare tumors present the challenge of small patient populations that may limit the efficient evaluation of novel agents alone or in combinations. Advances in mouse models and other preclinical methods are improving our ability to take only the most promising candidate therapies into clinical trials, however more work is needed to improve the predictability of these models and to reduce their cost. In addition, novel trial designs and endpoints are needed to meaningfully evaluate the activity of new agents in rare cancers. Patient advocacy groups play a key role in supporting research efforts, maximizing the number of patients available for clinical trials of rare tumor therapy, and can help make available rare and valuable biospecimens for basic research on the mechanisms of tumor pathogenesis and progression.

This meeting is organized by NCI, CCR's Rare Tumors Initiative to bring together basic and clinical researchers at the NIH working on rare tumors with extramural researchers, patient advocacy groups, industry, and the FDA to discuss current progress, future directions, and how to overcome the challenges facing rare tumors therapy development. These challenges will also be discussed in the context of developing individualized treatment for more common cancers. As individualized medicine becomes a reality, the group will focus on how to test and validate novel therapies in small numbers of patients. The goals of this symposium are to increase communication and build networks between researchers working in rare tumors across NIH, and to get input form patient groups, industry, and the FDA on how to overcome the biggest hurdles in the development of therapies for rare tumors.

General Information

For conference related questions please contact Dr. Abby Sandler or Dr. Karlyne Reilly


Natcher Conference Center, Balcony A
45 Center Dr.
Bethesda, MD

Spacer Image
Bottom Conference Border